Table 2

Indices of responsiveness at week 16 of follow up, for each treatment group, ordered by standardised response mean (SRM) of the combination group

Combined treatment (n=75)Sulfasalazine (n=79)t Value
Mean changeSEΔ SRM ESMean changeSEΔSRMES
Count core set measures ⩾20% improved5.90.2 4.1 4.10.22.25.7
Change in disease activity by patient, 7 point Likert2.60.1 3.5 1.70.21.25.3
Pooled index composite measure1.40.1 2.4 0.70.11.16.5
MACTAR interview120.6 2.2 3.28.50.81.32.13.7
Count core set measures ⩾50% improved4.60.2 2.2 2.40.31.06.0
Disease activity score (DAS) composite measure−2.10.1 1.9 1.9−1.20.11.01.24.9
AIMS pain scale−8.40.5 1.8 2.3−5.70.51.21.63.6
Health Assessment Questionnaire−1.10.1 1.5 1.5−0.40.10.80.66.2
Pain assessment by patient, VAS−3.30.3 1.5 1.6−1.80.30.70.84.0
Disease activity by patient, 5 point Likert−1.70.1 1.5 1.6−1.10.10.91.12.7
ESR (mm/1st h)−413 1.4 1.2−2330.90.74.1
Swollen joint count ARA 48−91 1.4 1.0−510.70.64.2
Grip strength (kPa)222 1.3 1.5810.60.45.8
Count core set measures ⩾70% improved3.00.3 1.3 1.40.20.74.8
Global assessment by observer, VAS−303 1.3 1.3−1430.60.74.3
Physical function by patient, 6 point Likert1.80.2 1.3 1.71.30.20.91.22.2
Tender joint count ARA 68−141 1.2 1.0−610.50.44.1
Ritchie Arthritis Index tender joints−101 1.2 1.0−710.80.62.5
CRP (mg/l)−334 0.9 0.8−1850.50.52.2
AIMS mobility scale5.30.7 0.9 1.02.10.50.50.33.9
Global assessment by patient, VAS−2.20.3 0.8 1.1−1.70.30.60.91.1
AIMS self efficacy scale5.10.8 0.8 0.92.40.60.40.42.7
  • SEΔ = standard error of change; SRM = standardised response mean; ES = effect size;t value, unpaired (i.e. between group). SRM 95% confidence intervals have a width of <0.5 around the listed value, between-SRMs differences ⩾0.35 are significant (two sided p<0.05, no correction for multiple comparison).